XANAX and XANAX TS (alprazolam) are indicated for the treatment of the anxious disorders or the short-term relief of the symptoms d' excessive anxiety. L' anxiety or the tension associated with the stress with the daily life does not justify l' in general; administration d' anxiolytique. Generalized anxious disorder: XANAX and XANAX TS are indicated in the treatment of the generalized anxious disorder (TAG). The TAG is characterized by an anxiety and an unrealistic or excessive concern (apprehension) about d' at least 2 factors of the daily life, being maintained at least 6 months, more than 1 day out of 2. At least 6 of the 18 following symptoms are often present among these patients: tension driving (tremors, spasms or impression of jolts, tension, pains or endolorissements muscular; agitation or impatience, fatigability); neurovégétative hyperactivity (impression of suffocation; palpitations or accelerated cardiac rhythm; perspiration or hands cold and moist; oral dryness; dizzy spells or feeling of light head; abdominal nauseas, diarrhoea and other embarrassments; puffs of heat or shivers; frequent micturitions; difficulty of swallowing or feeling of "ball in the throat"); exploration hypervigilante of l' environment (feeling d' to be boosted, reaction of exaggerated start; disorder of the concentration or "lapseen of memory" due to l' anxiety; difficulty with s' to deaden or to remain deadened; irritability). These symptoms should not be secondary with another psychiatric disorder and must not have any organic cause. Disorder panics with or without agoraphobia: XANAX and XANAX TS are also indicated for the treatment of the disorder panics, with or without agoraphobia. The disorder panic is characterized by recurring crises of panic. The crises of panic are discontinuous periods d' discomfort or of intense fear characterized by at least 4 of the following symptoms: dyspnea, dizzy spells, feeling d' instability or d' to be at the edge of l' muscular fainding, tachycardia, tremors or jolts, sweats, suffocation, nauseas or abdominal embarrassment, depersonalization or derealisation, paraesthesia, puffs of heat or shivers, pain or thoracic embarrassment, fear of dying, fear of becoming insane or fear of making an act not controlled. The crises last usually only a few minutes, but can, more rarely, to last jusqu' at a few hours. One diagnoses the disorder panics when the patient has at least 4 crises in l' space 4 weeks or one or more followed crises d' one period d' at least a month of persistent fear d' a new crisis. The symptoms should not be ascribable to known organic causes. The crises of panic are unexpected, at least at the beginning. Later, after evolution of the disease, certain situations, for example to lead a car or to move in a crowd, can be associated with the crises with panic. Those are not started by situations in which the subject is observed attentively by others (as in the social phobia). During the normal course of the disease, the patient often starts to present symptoms d' agoraphobia. L' agoraphobia is the fear of being in situations where it could be difficult of s' to escape or d' to obtain l' helps in the event of unexpected crises of panic. Because of this fear, the patient often limits his displacements or must be accompanied lorsqu' it s' move away from its residence, or, it endures agoraphobic situations in spite of an intense anxiety. L' intensity varies the light one (the patient can work or make its storing) with severe (the patient does not leave any more at his place). Demonstrations of l' effectiveness of l' alprazolam is limited to 4 months systematic clinical studies for the generalized anxious disorders and from 4 to 10 weeks for the disorder panics. However, of the people suffering from disorder panic were treated within the framework d' an open study during a 8 months maximum, without loss connects therapeutic benefits. The doctor must revalue with regular intervals l' utility of the medicamentous treatment among all patients.